Schroder Investment Management Group

Schroder Investment Management Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Schroder Investment Management Group’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.23M	Buy	104,356 +47,220	+83%	+$1.21M	﹤0.01%	907
2025 Q4	$1.6M	Buy	57,136 +594	+1%	+$15.2K	﹤0.01%	919
2025 Q3	$1.05M	Buy	+56,542	New	+$892K	﹤0.01%	1016
2024 Q3	–	Sell	-221,697	Closed	-$2.06M	–	1202
2024 Q2	$2.06M	Buy	221,697 +203,562	+1,122%	+$1.84M	﹤0.01%	925
2024 Q1	$180K	Buy	18,135 +6,737	+59%	+$50.3K	﹤0.01%	1177
2023 Q4	$34.4K	Hold	11,398	–	–	﹤0.01%	1178
2023 Q3	$63.6K	Buy	+11,398	New	+$96.9K	﹤0.01%	1184

Other funds holding ARQT

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return